SciSparc Subsidiary NeuroThera Labs Achieves Regulatory Milestone for Tourette Syndrome Clinical Trial

NeuroThera Labs Inc., a subsidiary of SciSparc Ltd., has achieved a regulatory milestone by completing the manufacturing and obtaining batch release certification for its Phase IIb clinical trial of SCI-110, a cannabinoid-based treatment for Tourette Syndrome. This certification allows the shipment of clinical trial materials to sites including the Yale Child Study Center and Hannover Medical School, facilitating the activation of these sites and the start of patient enrollment. The trial will assess the efficacy, safety, and tolerability of the drug candidate.